JPS6233204B2 - - Google Patents

Info

Publication number
JPS6233204B2
JPS6233204B2 JP53131448A JP13144878A JPS6233204B2 JP S6233204 B2 JPS6233204 B2 JP S6233204B2 JP 53131448 A JP53131448 A JP 53131448A JP 13144878 A JP13144878 A JP 13144878A JP S6233204 B2 JPS6233204 B2 JP S6233204B2
Authority
JP
Japan
Prior art keywords
isopropyl
active ingredient
blocker
dihydroergotamine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP53131448A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5490185A (en
Inventor
Mirabetsuku Maria
Wagunaa Heriberuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANDO AG
Original Assignee
SANDO AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANDO AG filed Critical SANDO AG
Publication of JPS5490185A publication Critical patent/JPS5490185A/ja
Publication of JPS6233204B2 publication Critical patent/JPS6233204B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP13144878A 1977-10-24 1978-10-24 Novel use of alpha intercepting agent Granted JPS5490185A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4414777 1977-10-24

Publications (2)

Publication Number Publication Date
JPS5490185A JPS5490185A (en) 1979-07-17
JPS6233204B2 true JPS6233204B2 (enExample) 1987-07-20

Family

ID=10432009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13144878A Granted JPS5490185A (en) 1977-10-24 1978-10-24 Novel use of alpha intercepting agent

Country Status (4)

Country Link
US (1) US4239763A (enExample)
JP (1) JPS5490185A (enExample)
IT (1) IT1157365B (enExample)
ZA (1) ZA785989B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5006526A (en) * 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
AR034204A1 (es) * 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
CN1582168A (zh) * 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
RU2756946C2 (ru) * 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Применение замещенных азетидинонов для лечения ситостеролемии
ES2296894T3 (es) * 2001-01-26 2008-05-01 Schering Corporation Combinaciones de ezetimiba con aspirina para tratar estados vasculares.
AU2002247019C1 (en) * 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
DE60216300T2 (de) * 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) * 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074847A (en) * 1960-04-27 1963-01-22 Frank L Bigsby Appetite control composition
FR5468M (enExample) * 1966-06-24 1967-10-16
CH520681A (de) * 1967-08-02 1972-03-31 Sandoz Ag Verfahren zur Herstellung neuer Mutterkornpeptidalkaloide
US4076715A (en) * 1972-09-26 1978-02-28 Sandoz Ltd. 13-Bromo lysergic acid compounds
JPS5332126A (en) * 1976-09-02 1978-03-27 Sandoz Ag Improvement in organic compound

Also Published As

Publication number Publication date
US4239763A (en) 1980-12-16
ZA785989B (en) 1980-06-25
JPS5490185A (en) 1979-07-17
IT7851429A0 (it) 1978-10-10
IT1157365B (it) 1987-02-11

Similar Documents

Publication Publication Date Title
JPS6233204B2 (enExample)
JP6875407B2 (ja) Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
FI117373B (fi) Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
SK31999A3 (en) Use of sibutramine analogues to prevent the development of diabetes
EP1259292A2 (en) Therapeutic agents
JP2007314578A (ja) 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠
JP2904827B2 (ja) 不安および不安抑うつ障害の処置に有用な医薬組成物の調製へのトリフルオロメチルフェニルテトラヒドロピリジンの使用
US3885035A (en) Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
EP1857442A3 (en) Novel antimycobacterial compounds
BRPI0610851A2 (pt) associação entre a ferroquina e um derivado de artemisinina, composição farmacêutica, utilização da referida associação e kit
JPS63130569A (ja) カルボン酸アミド含有薬剤
JPH07196492A (ja) 体重増加を抑制する、または体重減少を誘発するための医薬組成物
US4794111A (en) Dihydropyridine preparations containing β-blockers
JPH0140009B2 (enExample)
JP2665357B2 (ja) 心不全治療用医薬組成物
US7338955B1 (en) Medicament for treatment of neuropathies
US4122177A (en) Method of treating oligospermia and asthenospermia
CA2316853A1 (en) Potassium channel activators
JPH01316319A (ja) 医薬
NZ535261A (en) A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
EP2682109B1 (en) Combined immediate release formulations of flurbiprofen and famotidine
US3857944A (en) 1-piperazinoisoquinolines as inotropic agents
US4363809A (en) Organic compounds
CA2533492A1 (en) Use of 3,7-diazabicyclo[3,3,1]nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
US4085218A (en) Elevating mood in geriatric patients